Limited data is available regarding a total dose of BPG for early syphilis in HIV-infected patients, possibly causing substantial variation in the management of early syphilis for HIV-infected patients among clinicians [ 4].
Accordingly, no firm conclusions should be drawn regarding a potential dose-response relationship between the BMI/metabolic syndrome and BMI/insulin resistance categories.
Current evidence indicates that n-3 LCPUFA may also affect mood, behavior, and overall immune function, but the evidence does not allow recommendations regarding an exact dose.
From current evidence, according to ICRP 2011 a judgement can be made regarding a threshold acute dose of about 0.5 Gy (or 500 mSv) for both cardiovascular disease and cerebrovascular disease [ 3].
Regarding a possible linear dose-response, the adjusted risk ratio of all cancers at 100 mSv was 0.96 (95% CI 0.92 1.00) for paternal exposure and 1.01 (95% CI 0.98 1.04) for maternal exposure.
The results showed that positive attitudes regarding a once-weekly dosing regimen were common, with beneficial aspects perceived to include greater convenience, better medication adherence, improved quality of life, and a less overwhelming sense of treatment (p < 0.001 for all comparisons).
Therefore, concerns regarding a reduction in radiation dose have been recently raised during cerebral CTA acquisitions [ 19].
Between January 2013 and June 2015, 17 significant adverse events (SE) have been reported to the ASN (French Nuclear Safety Authority) regarding an error of dose fractionation or session frequency for the treatment of patients in external radiotherapy.
Regarding dosing, the dose of quetaipine XR in this study was relatively low, and the flexible dosing schedule might have confounded the results.
We found nothing relating to attendance versus non-attendance and to numbers of groups attended by participants that could be regarded as a dose effect.
